12 September 2017 - - Anthony M. Manning, Ph.D. has been appointed US-based biopharmaceutical company Palatin Technologies, Inc.'s (NYSE MKT: PTN) board of directors, the company said on Tuesday.

He currently serves as the senior vice president of research at Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), Cambridge, MA.

Manning is responsible for research and the discovery of novel products as the senior vice president of research at Momenta Pharmaceuticals, Inc.

Since joining Momenta, his team has advanced three novel autoimmune drugs into development.

Prior to Momenta, Manning was vice president and head of immunology research for Biogen Idec, Inc.

Before that, he was vice president and global head of inflammation, autoimmunity and transplantation research at Roche Pharmaceuticals.

Palatin Technologies is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.